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EGFRa b s t r a c t
Epidermal growth factor receptor (EGFR) is an effective molecular target of anti-cancer therapies. Curcu-
min inhibits cancer cell growth in vitro by suppressing gene expression of EGFR and reduces tumor
growth in various animal models. To overcome instable and insoluble properties of curcumin as thera-
peutics, we designed and synthesized six novel pyrimidine-substituted curcumin analogues with or with-
out a hydroxyl group originally present in curcumin. The cell viability tests indicated that IC50 of the
analogues containing hydroxyl group were 3 to 8-fold lower than those of the analogues without hydro-
xyl group in two colon cancer cell lines tested. Western blot analysis indicates the analogues containing
hydroxyl group inhibited expression and tyrosine phosphorylation of EGFR. Further protein analyses
showed that the analogues had anti-cellular proliferation, pro-apoptosis, and cell cycle arrest properties
associated with suppressed EGFR expression. These results indicate that the hydroxyl groups in curcumin
and the analogues were critical for observed biological activities.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Epithelial growth factor receptor familywith its most prominent
member of EGFR represents valid targets for anti-cancer therapy.
Anti-EGFRs MoAbs (cetuximab, panitumumab, and trastuzumab)
and TKIs (geﬁtinib, erlotinib, and lapatinib) have now been ap-
proved for the treatment of advanced colorectal cancer, squamous
cell carcinoma of the head and neck, advanced non small cell lung
cancer, as well as pancreatic and breast cancer because majority
of human cancers are originated from accumulated genetic muta-
tions of epithelia cells and many types of human cancers are asso-
ciated with over-expressed EGFR.1 However, the beneﬁts of costly
TKIs and anti-EGFRs MoAbs treatment to most cancer patients are
very limited due to complications of drug-resistant and side effects.
The median survival rates are only a few months more than those
patients treated with conventional therapies. Hence there is a great
need in developing inexpensive and more effective anti-EGFR
drugs.Curcumin, a compound that is responsible for tumeric thera-
peutic properties in traditional medicine, has been shown to inhi-
bit human colon cancer cell growth by suppressing gene
expression of EGFR through reducing the trans-activation activity
of Egr-1.2 Curcumin also inhibits a variety of tumor growth in var-
ious animal models such as mammary adenocarcinoma, stomach,
duodenal in addition to colon cancers.3–6 Therefore, understanding
the relationship between structure and biological activities of cur-
cumin will be important for developing novel anti-EGFR drugs.
Curcumin (Fig. 1) consists of a phenolic ring, alternating double
bond and b-dicarbonyl group, which form a conjugated p bond
skeleton,7 wherein the b-dicarbonyl group and substituted phenol
rings are the pharmacophore.8–12 Curcumin can exist in several
tautomeric forms, including a 1,3-diketo form and 2 equiv enolate
forms. The enolate form is more energetically stable in the solid
phase and in solution.13 Curcumin has poor water solubility due
to its rigid and planarity structure, which affects its absorption
from digestive system into blood circulation.14 Moreover, the b-
dicarbonyl group in curcumin is unstable and easily decomposed,
which leads to an even lower blood concentration and further re-
duces pharmacological potency of curcumin.14 Indeed, turmeric
containing 5% curcumin is pharmacological safe even when con-
sumed up to 100 g per day in diet.15,16 Thus, we have designed
and synthesized six novel pyrimidine-substituted curcumin ana-
logues with or without hydroxyl group in which the plane conju-
gate structure of curcumin was retained while the chemical
Figure 1. Chemical structure of curcumin.
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(Fig. 2).17
Colorectal cancer is one of the leading causes of cancer death in
the developed Western countries18 and increases in an alarming
rate in Asian.19 EGFR has been reported to be over-expressed from
25% to 82% in colorectal cancers.20 Therefore, we used two colon
cancer cell lines as a model system to understand the relationshipsFigure 2. Chemical stbetween structure and biological activity of curcumin analogues
towards EGFR regulations.
2. Results and discussion
2.1. Chemical synthesis of six novel primidine substituted
curcumin analogues
To retain the plane conjugate structure and to improve the
chemical stability and solubility in water and organic solvent of
curcumin, we used the following scheme to synthesize the curcu-
min analogues (Scheme 1).
Reagents and conditions: (i) 4,6-dimethyl-2-hydroxyl-pyrimi-
dine hydrochloride, HCl, EtOH, PhMe, 110 C, 36 h, 65–70%. (ii)
POCl3, DIPEA, 110 C, 12 h, 40–45%. (iii) Appropriate amine, EtOH,
90 C, 12 h, 52–69%.
4,6-Dimethyl-2-hydroxyl-pyrimidine hydrochloride was syn-
thesized in one-pot as previously reported.17
Compounds 4a–f were synthesized following the convergent
synthetic approach depicted in Scheme 1. The compounds 2a–b
were prepared from the appropriate aromatic aldehydes with
4,6-dimethyl-2-hydroxyl-pyrimidine hydrochloride according to
the procedure we reported previously.21
Subsequently, the compounds 3a–bwere synthesized by reﬂux-
ing a solution of 2a–bwith N,N-diethylaniline in an excess of POCl3
overnight in the yields of 40–45%. In the last step, target com-
pounds 4a–f could be prepared by reﬂuxing an ethanol solution
of the appropriate amine with compounds 3a–b in good yields
(52–69%). Comparing with curcumin, the target compounds 4a–f
can be dissolved in polar solvent such as ethanol and in water with
acid as well.ructures of 4a–f.
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Figure 3. Growth inhibitory effect of 4a–f on HCT116 and HT29 human colon cancer cells. HCT116 and HT29 were seeded in 96-well plates, respectively. After 24 h, cells
were treated with serial concentrations of curcumin analogues. After 48 h of treatment, cell viability was measured by resazurin assay as described under Materials and
Methods. Data are expressed as the mean ± standard deviation.
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Scheme 1. Synthesis of compounds 4a–f.
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effective than their counterparts in inhibiting colon cancer cell
growth
We compared the inhibitory effects of the six analogues on two
colon cancer cell lines using resazurin assay. Three curcumin ana-
logues with hydroxyl group were 4b, 4d, and 4f and their corre-
sponding curcumin analogues without hydroxyl group were 4a,
4c, and 4e, respectively. In both HCT116 and HT29 cells, all ﬁve
curcumin analogues except 4e in HT29 showed dose-dependentTable 1
Compound IC50 ± SDa (lM)
HT29 HCT116
4a 38.5 ± 25.4 46.4 ± 23.6
4b 7.1 ± 0.4 6.2 ± 1.2
4c >100 28.0 ± 12.7
4d 12.8 ± 1.9 9.9 ± 6.9
4e >100 21.9 ± 7.0
4f 12.4 ± 0.9 7.4 ± 1.8
a IC50, compound concentration required to inhibit cell proliferation by 50%.inhibition on the cell growth and the analogues with hydroxyl
group showed much stronger grow inhibition effects than their
corresponding curcumin analogues without hydroxyl group
(Fig. 3). For example, three curcumin analogues with hydroxyl
group (4b, 4d, and 4f) showed IC50 from 6.2 to 12.8 lM in both
cancer cells, while IC50 of the three analogues without hydroxyl
group (4a, 4c, and 4e) were 3 to 8-fold higher (from 21.9 to
>100 lM) (Table 1).
2.3. Analogue 4b suppressed EGFR expression and
phosphorylation
Curcumin is a component of turmeric. Turmeric is a spice derived
from amember of ginger family. Traditionalmedicine uses turmeric
for biliary disorders, anorexia, cough, diabetic wounds, hepatic dis-
orders, rheumatism, and sinusitis.22 Modern research indicates cur-
cumin is responsible formanyof tumeric therapeutic properties. It is
subsequently demonstrated that curcumin inhibits human colon
cancer cell growth by suppressing gene expression of EGFR.2
Data in Figure 3 and Table 1 showed that the curcumin ana-
logues inhibited the growth of two human colon cells. Since EGFR
might be the most important growth signaling pathway in the two
colon cancer cell lines, we then tested if the observed cytotoxicity
P. Qiu et al. / Bioorg. Med. Chem. 21 (2013) 5012–5020 5015was due to suppressed EGFR expression and phosphorylation by
the analogues.
As shown in Figure 4, after incubation with analogue 4a or 4b
for 72 h in both colon cancer cells, 4a at 20 lM concentration did
not signiﬁcantly decrease the levels of P-EGFR(Tyr1068) or EGFR
in both of HCT116 and HT29 cells. In contrast, 4b signiﬁcantly de-
creased the levels of both phosphorylated P-EGFR(Tyr1068) and
EGFR in a concentration-dependent manner.
2.4. Analogue 4b induced cell cycle arrest in a concentration-
dependent manner
It was reported that curcumin inhibits HT29 colon cancer cell
growth by suppressing gene expression of EGFR.2 We found that
the curcumin analogues inhibited EGFR expression and phosphor-
ylation in both HT29 and HCT116 cells (Fig. 4). It was reported in
literature that HCT116 cells treated with curcumin are largely
accumulated in G2/M phase.23 We thus tested how the curcumin
analogues affect cell cycles in both HCT116 and HT29 cells. As
shown in Figure 5A (HCT116 cells), 4a at the concentration of
20 lM and 4b at the concentrations of 5, 10, and 20 lM increased
G2/M cell population to 1.03-, 1.54-, 1.78-, and 2.05-fold of that of
the control cells, respectively. In HT29 cells (Fig. 5B), 4a at the con-
centration of 20 lM and 4b at the concentrations of 5, 10, and
20 lM increased G2/M cell population to 1.10-, 1.86-, 1.94-, and
2.40-fold of that of the control cells, respectively. Interestingly,
4b at 5 lM concentration induced G0/G1 cell cycle arrest in both
HCT116 and HT29 cells.
It was reported that curcumin induced G2/M cell cycle arrest is
accompanied by increased p21WAF-1/CIP-1 expression.5 p21WAF-1/CIP-1
is a potent cyclin-dependent kinase inhibitor (CKI). p21WAF-1/CIP-1
binds to and inhibits the activity of cyclin-CDK2 or cyclin-CDK1
complexes, and thus functions as a regulator of cell cycle progres-
sion. Since 4b at 5 lM concentration induced both G0/G1 and G2/
M cell cycle arrests (Fig. 5A and B), we assessed cell cycle signaling
checkpoint proteins, including p21WAF-1/CIP-1, CDK2, CDK4, Cyclin
D1, Cyclin E1, and Rb systematically in HCT116 cells after treating
the cells with or without the analogues. Rb stands for retinoblas-
toma protein, which is a tumor suppressor protein that is dysfunc-P-EGFR(Tyr1068)
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Figure 4. Effects of the curcumin analogues on EGFR and P-EGFR (Tyr1068) in
human colon cancer cells HCT116 and HT29. Both cells were seeded in 15 cm dishes
for 24 h, and then cells were treated with 4a at 20 lM or 4b at 5, 10 and 20 lM,
respectively. After 72 h of incubation, cells were harvested for Western blotting
analysis. The numbers underneath the blots represent band intensities (normalized
to the loading controls, means of three independent experiments) measured by the
Image J software. The standard deviations were all within ±15% of the means (data
not shown). b-Tubulin was used as equal loading controls. The experiments were
repeated for three times.tional in several major cancers. One function of Rb is to prevent
excessive cell growth by inhibiting cell cycle progression.
As shown in Figure 5C, 4a at 20 lM and 4b at 5, 10, and 20 lM
concentrations induced signiﬁcant p21WAF-1/CIP-1 expression (20.0,
21.4, 28.6, and 25.7 fold-increases, respectively). Analogue 4a at
20 lM did not induce signiﬁcant changes in all other proteins
tested. In contrast, 4b inhibited expression of Cyclin D1, Cyclin
E1, and Rb in a concentration-dependent manner even though 4b
did not induce signiﬁcant changes in CDK2 and CDK4 proteins at
all concentrations tested.
We concluded from the data in Figure 5 that the curcumin ana-
logues, especially 4b, caused cell cycle arrest in both HCT116 and
HT29 human colon cancer cells by inducing signiﬁcant p21WAF-1/
CIP-1 expression. Analogue 4b also inhibited CyclinD1, CyclinE1,
and Rb expression in a concentration-dependent manner.
2.5. Effects of the curcumin analogues on proteins involved in
apoptosis
Studies indicated that intracellular caspases are one of the ma-
jor signaling pathways involved in apoptotic cell death. Caspases
are a family of structurally related cysteine proteases. For example,
caspases-2, -3, -6, -7 and -9 can cleave poly (ADP ribose) polymer-
ase (PARP).24 Curcumin was reported to activate caspases 3, 8, and
9 in the colon cancer cell lines SW480 and SW620.25
We ﬁrst examined the expression levels of activated caspase 3
and cleaved PARP because PARP is a substrate of caspase 3 after
treating the HCT116 colon cancer cells with or without the ana-
logues. As shown in Figure 6A, 4a at 20 lM concentration did not
cause any noticeable change in both caspase 3 and PARP. In con-
trast, 4b caused activated caspase 3 and cleaved PARP in a concen-
tration-dependent manner.
Heat shock proteins (HSP) are a class of functionally related pro-
teins involved in the folding and unfolding of other proteins. Their
expression is increased when cells are exposed to elevated temper-
atures or other stress including harmful chemicals. It has been
established that HSP70 directly inhibits apoptosis whereas HSP90
stabilizes various growth factor receptors including EGFR. Hence
inhibition of HSP90 may induce apoptosis.26 We found that 4a at
20 lM concentration had no effect on the expression of HSP-70
and HSP-90, while 4b decreased the levels of HSP90 and HSP70
expressions in a concentration-dependent manner.
Bcl-2 is a family of evolutionarily related proteins. These pro-
teins govern mitochondrial outer membrane permeabilization
and can be either pro-apoptotic, such as Bax, or anti-apoptotic such
as Bcl-2.27 We measured the levels of Bcl-2 and Bax expression in
HCT116 colon cancer cells after treating the cells with different
concentrations of 4a and 4b for 72 h. Compound 4a decreased
slightly the level of anti-apoptotic Bcl-2 expression but increased
the level of pro-apoptotic protein Bax expression (Fig. 6B). Com-
pound 4b had a stronger effect on the expression of Bcl-2 and
Bax and the effect was concentration-dependent.
A quantiﬁcation of BAX and Bcl-2 expression indicated that 4a
at 20 lM concentration increased the ratio of Bax/Bcl-2 by 1.57-
fold compared to the untreated control, whereas 4b increased
the ratio of Bax/Bcl-2 by 2.1-, 17-, and 19-fold at 5, 10, and
20 lM concentrations, respectively. Therefore, the curcumin ana-
logues worked on multiple protein targets to promote apoptosis
in the human colon cell line HTC116, which was consistent with
the multiple functions of EGFR signaling.
3. Conclusions
In summary, we describe the synthesis of six novel pyrimidine-
substituted curcumin analogues with or without hydroxyl group in
which the critical plane conjugate structure of curcumin was
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Figure 5. Cell cycle-related analysis of human colon cancer cells after treating with the curcumin analogues. HCT-116(A) and HT29 (B) cells after treating with the curcumin
analogues 4a or 4b. The HCT116 and HT29 cells were seeded in 6-well plates (4  104/ml, 2 ml/well) for 24 h, and then the cells were treated with 4a at 20 lM or 4b at 5, 10
and 20 lM concentrations. After 24 h, cells were harvested and subject to cell cycle analyses as described in Section 4. All results shown are mean ± SD, and are representative
of three independent assays. Statistical analyses were conducted among control and treated groups in G0/G1, S, and G2/M phases. (C) Effects of 4a and 4b on cell cycle related
proteins in HCT116 human colon cancer cells.
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The cell viability tests indicated that IC50 of the three curcumin
analogues containing hydroxyl group was 3 to 8-fold lower than
that of the three analogues without hydroxyl group in two colon
cancer cell lines tested. Western blot analysis indicates the ana-
logues containing hydroxyl group inhibited expression and tyro-
sine phosphorylation of EGFR. Cell cycle and further cell cycle
and apoptotic check point protein analyses showed that the ana-
logues had expected anti-cellular proliferation, pro-apoptosis,
and cell cycle arresting properties associated with suppressed
EGFR expression and activation. These results suggest that the hy-
droxyl group in curcumin and the analogues (Fig. 7) might be crit-
ical for EGFR regulating activities.4. Experimental section
4.1. Cell culture
Human colon cancer cells HCT116 and HT29 were obtained
from Shanghai Cell Bank of Chinese Academy of Science (China)
and were maintained in McCoy’s 5A (Sigma–Aldrich) supple-
mented with 5% heat inactivated FBS (Hyclone), 100 U/mL of pen-
icillin, and 0.1 mg/mL streptomycin (Sigma–Aldrich) at 37 C with
5% CO2 and 95% air. Cells were kept subconﬂuent, and media were
changed every other day. All cells used were within 3–30 passages.
DMSO was used to dissolve the six curcumin analogues, and the ﬁ-
nal concentration of DMSO in all culture media was 0.1%. PI/RNase
CDK4
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Fig. 5 (continued)
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chemicals are of analytical grade.
4.2. General methods for chemical synthesis
All starting materials and solvents were obtained from com-
mercial sources and used without further puriﬁcation. Thin-layer
chromatography (TLC) was performed on precoated E. Merck sil-
ica-gel 60 F254 plates. Column chromatography was performed
on silica gel (200–300 mesh). Melting points were determined on
a Mitamura–Riken micro-hot stage and were not corrected. 1H
NMR and 13C NMR spectra were obtained on a Jeol JNM-ECP 600
spectrometer with tetramethylsilane (Me4Si) as the internal stan-
dard, and chemical shifts were recorded in d values. Mass spectra
were recorded on a Q-TOF Global mass spectrometer.
4.3. General procedure for the synthesis of compounds 4a–f
4,6-Dimethyl-2-hydroxyl-pyrimidine hydrochloride (1 equiv)
and appropriate substituted benzaldehydes (3 equiv) were dis-
solved in anhydrous ethyl alcohol and toluene in a round-bot-
tomed ﬂask (500 mL). Then concentrated hydrochloric acid
(3 equiv) was added and the mixture was reﬂuxed at 100 C for
36 h. After completion of the reaction, the solvent was evaporated
under reduce pressure. The saturated NaHCO3 solution (250 mL)
was added into the brown oil residue for desalting. After stirring
at room temperature for 5 h, the resulting precipitate was ﬁltered
and washed with water and ether to obtain crude product and then
puriﬁed by chromatography on silica gel (eluent, dichloromethane/
methanol) to give 2a–b as brown powder.
4.3.1. (E,E)-4,6-Bis(3,4-dimethoxystyryl)-2-hydroxyl-pyrimidine
(2a)
The titled compound 2a was obtained from 4,6-dimethyl-2-hy-
droxyl-pyrimidine hydrochloride (2.18 g, 15 mmol), 3,4-dime-
thoxybenzaldehyde (7.48 g, 45 mmol), conc HCl (3.75 mL
45 mmol), anhydrous EtOH (150 mL) and toluene (50 mL) accord-
ing to the procedure described above as brown powder (4.41 g,
70%): Rf = 0.20 (CHCl3/MeOH 9:1); mp: 255–257 C; 1H NMR
(600 MHz, [D6]DMSO): d = 11.55 (s, 1H), 7.80–7.77 (d,
J = 17.28 Hz, 2H), 7.29 (s, 2H), 7.20 (d, J = 7.74 Hz, 2H), 7.04–7.02
(d, J = 7.92 Hz, 2H), 6.94–6.92 (d, J = 15.42 Hz, 2H), 6.85 (s, 1H),
3.84 (s, 6H), 3.81 ppm (s, 6H); 13C NMR (150 MHz, [D6]DMSO):d = 151.1, 149.6, 138.8, 128.6, 122.7, 112.3, 110.4, 56.1 ppm; MS
(ESI) m/z 421.2 [M+H]+.
4.3.2. (E,E)-4,6-Bis(3,4,5-trimethoxystyryl)-2-hydroxyl-
pyrimidine (2b)
The titled compound 2b was obtained from 4,6-dimethyl-2-hy-
droxyl-pyrimidine hydrochloride (2.18 g, 15 mmol), 3,4,5-trimeth-
oxybenzaldehyde (8.83 g, 45 mmol), conc HCl (3.75 mL 45 mmol),
anhydrous EtOH (150 mL) and toluene (50 mL) according to the
procedure described above as brown powder (4.68 g, 65%):
Rf = 0.20 (CHCl3/MeOH 9:1); mp: 222–224 C, 1H NMR (600 MHz,
[D6]DMSO): d = 11.71 (s, 1H), 7.79 (d, J = 16.5 Hz, 2H), 6.99 (m,
7H); 3.85 (s, 12H); 3.71 ppm (s, 6H); 13C NMR (150 MHz, [D6-
]DMSO): d = 153.7, 139.6, 139.0, 131.4, 107.6, 105.7, 67.2, 60.7,
56.5 ppm; MS (ESI) m/z 481.2 [M+H]+.
General method for the synthesis of compounds (3a–b). A
mixture of compound 2a–b (3.0 mmol) and POCl3 (25 mL) was
stirring in a round-bottomed ﬂask (50 mL), then DIPEA (1 mL,
5.8 mmol) was added and the mixture was reﬂuxed at 100 C
for 2 h. After completion of the reaction, the POCl3 was evapo-
rated under reduce pressure and the residue was poured into cold
saturated NaHCO3 solution. The precipitate was collected by ﬁl-
tration and washed with water to give crude product. The crude
product was puriﬁed through column chromatography on silica
gel (eluent dichloromethane/methanol) to give compounds 3a–b
as yellow powder.
4.3.3. (E,E)-4,6-Bis(3,4-dimethoxystyryl)-2-chloro-pyrimidine
(3a)
The title compound 3awas obtained from 2a (1.26 g, 3.0 mmol),
POCl3 (25 mL) and DIPEA (1 mL, 5.8 mmol) according to the proce-
dure described above as yellow powder (591 mg, 45%): Rf = 0.90
(CH2Cl2/MeOH 20:1); mp: 108–110 C; 1H NMR (600 MHz, CDCl3):
d = 7.85 (d, J = 15.9, 2H), 7.16–7.15 (dd, J = 8.22, 1.44, 2H), 7.12–
7.11 (d, J = 2.22, 2H), 7.05 (s, 2H), 6.90 (s, 1H), 6.88 (s, 1H), 6.86
(d, J = 15.96, 2H), 3.92 (s, 6H), 3.91 ppm (s, 6H); 13C NMR
(150 MHz, CDCl3): d = 165.8, 161.5, 150.8, 149.3, 138.6, 128.4,
122.5, 122.2, 113.8, 111.2, 109.6, 56.0 ppm; MS (ESI) m/z 439.1
[M+H]+.
4.3.4. (E,E)-4,6-Bis(3,4,5-trimethoxystyryl)-2-chloro-pyrimidine
(3b)
The title compound 3b was obtained from 2b (1.44 g,
3.0 mmol), POCl3 (25 mL) and DIPEA (1 mL, 5.8 mmol) according
to the procedure described above as yellow powder (672 mg,
45%): Rf = 0.80 (CH2Cl2/MeOH 20:1); mp: 104–106 C; 1H NMR
(600 MHz, CDCl3): d = 7.85–7.82 (d, J = 15.84, 2H), 7.19 (s, 1H),
6.93–6.91 (d, J = 15.42, 2H), 6.83 (s, 4H), 3.91 (s, 12H), 3.90 ppm
(s, 6H); 13C NMR (150 MHz, CDCl3): d = 165.64, 161.54, 153.57,
139.91, 138.81, 130.89, 123.82, 114.24, 105.11, 56.24 ppm; MS
(ESI) m/z 499.1 [M+H]+.
General method for the synthesis of compounds (4a–f). A mix-
ture of compound 3a–b (1 mmol) and appropriate amine
(10 mmol) in anhydrous EtOH (50 mL) was stirred at 90 C for
12 h and monitored with TLC. When the reaction was ﬁnished,
the solvent was evaporated under reduce pressure and the residue
was puriﬁed by column chromatography (silica gel dichlorometh-
ane/methanol) to yield the desired compounds.
4.3.5. 4,6-Bis((E)-3,4-dimethoxystyryl)-N-ethylpyrimidin-2-
amine (4a)
The title compound 4a was obtained from 3a (0.44 g 1 mmol),
ethylamine (3 mL) and anhydrous EtOH (50 mL) according to the
procedure described above as yellow powder (232 mg, 52%):
Rf = 0.50 (CH2Cl2/MeOH 20:1); mp: 74–76 C; 1H NMR (600 MHz,
CDCl3): d = 7.71 (d, J = 15.9, 2H), 7.14 (d, J = 6.6, 4H), 6.88 (d,
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Figure 6. Effects of the curcumin analogues on apoptosis-related proteins in HCT116 human colon cancer cells after treating with the curcumin analogues. HCT116 cells were
seeded in 15 cm dishes for 24 h, and then cells were treated with 4a at 20 lM or 4b at 5, 10 and 20 lM. After 72 h of incubation, cells were harvested for Western blotting
analysis as described in Section 4. The numbers underneath of the blots represent band intensity (normalized to b-actin, means of three independent experiments) measured
by Image J software. The standard deviations were all within ±15% of the means (data not shown). b-Actin was served as an equal loading control. The experiments were
repeated three times.
5018 P. Qiu et al. / Bioorg. Med. Chem. 21 (2013) 5012–5020J = 8.82, 2H), 6.84 (s, 1H), 6.81 (s, 1H), 6.67 (s, 1H), 5.32 (t, J = 6.6,
1H), 3.95 (s, 6H), 3.91 (s, 6H), 3.58 (m, 2H), 1.29 ppm (t, J = 8.34,
3H); 13C NMR (150 MHz, CDCl3): d = 163.70, 162.50, 150.10,
149.22, 135.45, 129.28, 125.03, 121.60, 111.16, 109.39, 106.45,
56.02, 36.45, 15.24 ppm; HRMS m/z [M+H]+ calculated for
C26H30N3O4: 448.2231, found 448.2225.
4.3.6. 2-(4,6-Bis((E)-3,4-dimethoxystyryl)pyrimidin-2-
ylamino)ethanol (4b)
The title compound 4b was obtained from 3a (0.44 g 1 mmol),
2-aminoethanol (3 mL) and anhydrous EtOH (50 mL) according to
the procedure described above as yellow powder (315 mg, 68%):
Rf = 0.45 (CH2Cl2/MeOH 20:1); mp: 145–147 C; 1H NMR
(600 MHz, CDCl3): d = 7.66 (d, J = 15.9, 2H), 7.15 (d, J = 2.16, 1H),
7.13 (d, J = 2.22, 1H), 7.12 (d, J = 1.68, 2H), 6.88 (d, J = 8.22, 2H),
6.82 (s, 1H), 6.79 (s, 1H), 6.71 (s, 1H), 5.53 (t, J = 5.79, 1H), 3.94
(s, 6H), 3.92 (s, 6H), 3.91 (t, J = 4.98, 2H), 3.70 ppm (q, J = 5.46,
2H); 13C NMR (150 MHz, CDCl3): d = 163.9, 163.0, 150.3, 149.2,136.1, 129.0, 124.4, 121.7, 111.2, 109.4, 107.0, 64.7, 56.0,
45.1 ppm; HRMS m/z [M+H]+ calcd for C26H30N3O5: 464.2180,
found 464.2187.
4.3.7. 4,6-Bis((E)-3,4-dimethoxystyryl)-N-propylpyrimidin-2-
amine (4c)
The title compound 4c was obtained from 3a (0.44 g 1 mmol),
propylamine (3 mL) and anhydrous EtOH (50 mL) according to
the procedure described above as yellow powder (258 mg, 56%):
Rf = 0.40 (CH2Cl2/MeOH 20:1); mp: 67–69 C; 1H NMR (600 MHz,
CDCl3): d = 7.71 (d, J = 15.4, 2H), 7.13 (d, J = 4.38, 4H), 6.87 (d,
J = 8.82, 2H), 6.83 (d, J = 15.4, 2H), 6.66 (s, 1H), 5.09 (t, J = 5.49,
1H), 4.12 (q, J = 7.14, 2H), 3.94 (s, 6H), 3.90 (s, 6H), 3.52 (q,
J = 6.87, 2H), 1.16 (m, 2H), 1.25 (t, J = 7.14, 3H), 1.03 ppm (t,
J = 7.41, 3H); 13C NMR (150 MHz, CDCl3): d = 163.7, 162.7, 150.0,
149.2, 135.3, 129.3, 125.1, 121.5, 111.2, 109.4, 106.3, 56.0, 43.4,
23.1, 11.7 ppm; HRMS m/z [M+H]+ calcd for C27H32N3O4:
462.2387, found 461.2382.
Figure 7. Enolate form of curcumin might be critical for EGFR regulating activities.
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ylamino)propan-1-ol (4d)
The title compound 4d was obtained from 3a (0.44 g 1 mmol),
3-amino-1-propanol (3 mL) and anhydrous EtOH (50 mL) accord-
ing to the procedure described above as yellow powder (253 mg,
53%): Rf = 0.34 (CH2Cl2/MeOH 20:1); mp: 142–144 C; 1H NMR
(600 MHz, CDCl3): d = 7.64 (d, J = 15.9, 2H), 7.14 (d, J = 1.62, 1H),
7.12 (s, 1H), 7.11 (s, 2H), 6.87 (d, J = 8.28, 2H), 6.81 (d, J = 15.9,
2H), 6.7 (s, 1H), 5.56 (t, J = 6.6, 1H), 3.93 (s, 6H), 3.90 (s, 6H),
3.72(q, J = 6.33, 2H), 3.68 (t, J = 5.52, 2H), 1.79 ppm (m, 2H); 13C
NMR (150 MHz, CDCl3): d = 163.9, 163.0, 150.3, 149.2, 136.1,
128.9, 124.3, 121.7, 111.1, 109.4, 106.2, 58.4, 55.9, 37.2,
33.3 ppm; HRMS m/z [M+H]+ calcd for C27H32N3O5: 478.2336,
found 478.2330.
4.3.9. 4,6-Bis((E)-3,4,5-trimethoxystyryl)-N-propylpyrimidin-2-
amine (4e)
The title compound 4e was obtained from 3b (0.50 g 1 mmol),
propylamine (3 mL) and anhydrous EtOH (50 mL) according to
the procedure described above as yellow powder (339 mg, 65%):
Rf = 0.35 (CH2Cl2/MeOH 20:1); Mp:102–104 C; 1H NMR (CDCl3,
600 M) d 7.69 (2H, d, J = 15.9), 6.87 (2H, d, J = 15.9), 6.81 (4H, s),
6.70 (1H, s), 5.11–5.10 (1H, t, J = 5.22), 3.91–3.88 (18H, s), 3.51–
3.50 (2H, q, J = 6.6), 1.62–1.67 (2H, m), 1.05–1.01 (3H, t, J = 7.41)
ppm; 13C NMR (CDCl3, 150 M) d 163.5, 162.7, 153.4, 139.0, 135.5,
131.8, 126.4, 106.5, 104.6, 61.0, 56.2, 43.4, 23.1, 11.7 ppm; HRMS
(ESI) m/z calcd for C29H36N3O6+ 522.2599, found 522.2584.
4.3.10. 3-(4,6-Bis((E)-3,4,5-trimethoxystyryl)pyrimidin-2-
ylamino)propan-1-ol (4f)
The title compound 4fwas obtained from 3b (0.50 g 1 mmol), 3-
amino-1-propanol (3 mL) and anhydrous EtOH (50 mL) according
to the procedure described above as yellow powder (376 mg,
70%): Rf = 0.30 (CH2Cl2/MeOH 20:1); mp: 102–104 C; 1H NMR
(600 MHz, CDCl3): d = 7.64 (d, J = 15.9, 2H), 6.88 (d, J = 15.36, 2H),
6.81 (s, 4H), 6.74 (s, 1H), 5.30–5.28 (t, J = 6.87, 1H), 3.91 (s, 12H),
3.89 (s, 6H), 3.76–3.73 (q, J = 6.22, 2H), 3.69–3.68 (t, J = 5.22, 2H),
1.83–1.79 ppm (m, 2H); 13C NMR (150 MHz, [D6]DMSO):
d = 163.18, 153.51, 139.35, 136.22, 131.59, 125.95, 106.82,
104.78, 61.08, 58.42, 56.25, 37.24, 33.42 ppm; HRMS m/z [M+H]+
calcd for C29H36N3O7: 538.2548, found 538.2537.4.4. Cellular viability assay
For cellular viability assay, a 96-wells plate (Nest) was seeded
with 2000 cells/well in complete medium. After 24 h, the medium
was removed and 200 lL complete medium containing different
amount of drugs was added to each well. The cells were incubated
for 48 h, followed by adding 20 lL of resazurin (2 mg/mL dissolved
in water, catalog no. R7017-5G, Sigma) to the media for 16 h. The
ﬂuorescent signal was monitored using 544 nm excitation wave-
length and 595 nm emission wavelength by Spectramax M5 plate
reader (Molecular Devices). The relative ﬂuorescence unit (RFU)
generated from the assay was proportional to the number of living
cells in each well.28 The IC50 value of each drug was calculated by
the Logit approach.
4.5. Cell cycle analyses
HCT116 and HT29 cells were seeded in 6-well plates
(4  104 cells/ml, 2 ml/well). After 24 h incubation for attach-
ment, cells were treated with or without different amount of
4a or 4b in 2 ml of complete media. After another 24 h, media
was collected and combined with adherent cells that were de-
tached by brief trypsinization (0.25% trypsin-EDTA; Sigma–Al-
drich). Cell pellets were washed with 1 ml of ice-cold PBS two
times and then resuspended in 1 ml of 70% ethanol in 4 C over-
night. After centrifugation (1600g, 1 min), the supernatant was
removed and cells were incubated with 0.5 ml of PI/RNase stain-
ing buffer for 15 min at room temperature. Single-cell suspension
was generated by gentle pipetting. Cell cycle was analyzed using
a FC500 MCL/MPL cell analyzer and data were processed using
MultiCycle software.29
4.6. Whole cell lysate preparation
Cells were seeded in cell culture dishes at a density of 8  104 -
cells/ml and 20 ml per dish in McCoy’s 5A medium containing 5%
FBS for 24 h. Different amount of 4a or 4bwere then added directly
to the medium of the cultured cells and incubated for another 72 h.
Cells were rinsed with PBS and total cell lysates were prepared by
adding 200 lL of whole cell lysis buffer containing 20 mM Tris–
HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM
Na3VO4, 1 lg/ml leupeptin (pH 7.5) to each dish and collected with
cell scrapers into microcentrifuge tubes. Cell suspensions were
then subjected to sonication (5s, three times). After further incuba-
tion for 30 min, supernatants were collected by centrifugation at
10,000g for 10 min.30 Protein concentrations were determined by
BCA protein assay kit (Beyotime Institute of Biotechnology, China),
following manufacturer’s instruction.
4.7. Preparation of cell membrane fraction
Trypsinized cells were washed with ice-cold PBS and then incu-
bated in the presence of buffer (10 mM Tris–HCl, pH 7.5, 1 mM
EDTA, 0.1 mM DTT) containing protease inhibitor cocktail (1 mM
Na3VO4, 1 mM leupeptin, 1 mM PMSF). The cell suspension was
sonicated 3s on ice four times followed by centrifugation at
100,000g for 1 h. The pellets were solubilized with lysis buffer
(20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1% Triton,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate) sup-
plemented with protease inhibitor cocktail (1 mM Na3VO4, 1 mM
leupeptin, 1 mM PMSF) on ice for 30 min after thorough mixing.
After centrifugation at 10,000g for 30 min, the cell membrane frac-
tion present in supernatant was collected.29
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For immunoblot analyses, equal amounts of proteins (20–
300 lg, depending on the proteins of interest) were subjected to
12% SDS–polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes. The membranes were incubated in
blocking buffer (Tris–buffered saline-0.05% Tween-20 (TBST) con-
taining 5% nonfat milk) at room temperature for 1 h, then incu-
bated with appropriate antibodies according to the protocols of
the manufacturers and washed with TBST. After incubation with
appropriate secondary antibodies, the membranes were washed
three times with Tris–buffered saline containing Tween-20 and
then visualized using enhanced chemiluminescence. Antibodies
for PARP, BAX, Bcl-2, HSP-70, HSP-90, p21WAF-1/CIP-1, P-EGFR
(Tyr1068), Rb, cyclinD1, cleaved caspase-3, caspase-8, CDK-2,
CDK-4 and b-actin were obtained from Cell Signaling Technology,
Inc. Antibodies for EGFR, cyclin E1, b-tubulin were purchased from
Immunoway, Inc.
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